These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 37290495)
1. A FOXC2 inhibitor, MC-1-F2, as a therapeutic candidate for targeting EMT in castration-resistant prostate cancer. Castaneda M; Rodriguez L; Oh J; Cagle-White B; Suh H; Abdel Aziz MH; Lee J Bioorg Med Chem Lett; 2023 Jul; 91():129369. PubMed ID: 37290495 [TBL] [Abstract][Full Text] [Related]
2. Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial-mesenchymal Transition in Aggressive Variant Prostate Cancers. Mitra Ghosh T; Mazumder S; Davis J; Yadav J; Akinpelu A; Alnaim A; Kumar H; Waliagha R; Church Bird AE; Rais-Bahrami S; Bird RC; Mistriotis P; Mishra A; Yates CC; Mitra AK; Arnold RD Cancer Res Commun; 2023 Jul; 3(7):1286-1311. PubMed ID: 37476073 [TBL] [Abstract][Full Text] [Related]
3. FOXC2 expression and epithelial-mesenchymal phenotypes are associated with castration resistance, metastasis and survival in prostate cancer. Børretzen A; Gravdal K; Haukaas SA; Beisland C; Akslen LA; Halvorsen OJ J Pathol Clin Res; 2019 Oct; 5(4):272-286. PubMed ID: 31464093 [TBL] [Abstract][Full Text] [Related]
4. Androgens induce a distinct response of epithelial-mesenchymal transition factors in human prostate cancer cells. Colditz J; Rupf B; Maiwald C; Baniahmad A Mol Cell Biochem; 2016 Oct; 421(1-2):139-47. PubMed ID: 27562825 [TBL] [Abstract][Full Text] [Related]
5. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N; Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502 [TBL] [Abstract][Full Text] [Related]
6. Androgens modify therapeutic response to cabazitaxel in models of advanced prostate cancer. Begemann D; Wang Y; Yang W; Kyprianou N Prostate; 2020 Sep; 80(12):926-937. PubMed ID: 32542812 [TBL] [Abstract][Full Text] [Related]
7. Cdc20/p55 mediates the resistance to docetaxel in castration-resistant prostate cancer in a Bim-dependent manner. Wu F; Lin Y; Cui P; Li H; Zhang L; Sun Z; Huang S; Li S; Huang S; Zhao Q; Liu Q Cancer Chemother Pharmacol; 2018 Jun; 81(6):999-1006. PubMed ID: 29605876 [TBL] [Abstract][Full Text] [Related]
8. [COST ANALYSIS OF ANDROGEN DEPRIVATION THERAPY AND DRUGS FOR CASTRATION-RESISTANT PROSTATE CANCER]. Nishizawa K; Hattahara K; Onishi H; Yoshida T Nihon Hinyokika Gakkai Zasshi; 2021; 112(2):53-57. PubMed ID: 35444081 [TBL] [Abstract][Full Text] [Related]
9. Interleukin-6/signal transducer and activator of transcription 3 promotes prostate cancer resistance to androgen deprivation therapy via regulating pituitary tumor transforming gene 1 expression. Huang S; Liu Q; Liao Q; Wu Q; Sun B; Yang Z; Hu X; Tan M; Li L Cancer Sci; 2018 Mar; 109(3):678-687. PubMed ID: 29288516 [TBL] [Abstract][Full Text] [Related]
10. A Forkhead Box Protein C2 Inhibitor: Targeting Epithelial-Mesenchymal Transition and Cancer Metastasis. Castaneda M; Chen L; Pradhan L; Li S; Zein R; Lee Y; Lim HS; Nam HJ; Lee J Chembiochem; 2018 Jul; 19(13):1359-1364. PubMed ID: 29577543 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo. Wang M; Liu X; Guo J; Weng X; Jiang G; Wang Z; He L Biochem Biophys Res Commun; 2015 Nov; 467(2):310-5. PubMed ID: 26435505 [TBL] [Abstract][Full Text] [Related]
13. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer. Martin SK; Kyprianou N Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899 [TBL] [Abstract][Full Text] [Related]
14. Combination treatment with docetaxel and histone deacetylase inhibitors downregulates androgen receptor signaling in castration-resistant prostate cancer. Park SE; Kim HG; Kim DE; Jung YJ; Kim Y; Jeong SY; Choi EK; Hwang JJ; Kim CS Invest New Drugs; 2018 Apr; 36(2):195-205. PubMed ID: 29110173 [TBL] [Abstract][Full Text] [Related]
15. Novel CIL-102 derivatives as potential therapeutic agents for docetaxel-resistant prostate cancer. Miller DR; Tzeng CC; Farmer T; Keller ET; Caplan S; Chen YS; Chen YL; Lin MF Cancer Lett; 2018 Nov; 436():96-108. PubMed ID: 30077739 [TBL] [Abstract][Full Text] [Related]
16. Functional analysis of GCNT3 for cell migration and EMT of castration-resistant prostate cancer cells. Yamamoto D; Sasaki K; Kosaka T; Oya M; Sato T Glycobiology; 2022 Sep; 32(10):897-908. PubMed ID: 35867813 [TBL] [Abstract][Full Text] [Related]
18. Phenotypes of circulating tumour cells predict time to castration resistance in metastatic castration-sensitive prostate cancer. Yang YJ; Kong YY; Li GX; Wang Y; Ye DW; Dai B BJU Int; 2019 Aug; 124(2):258-267. PubMed ID: 30536520 [TBL] [Abstract][Full Text] [Related]
19. Androgen receptor negatively regulates mitotic checkpoint signaling to induce docetaxel resistance in castration-resistant prostate cancer. Pilling A; Kim SH; Hwang C Prostate; 2022 Feb; 82(2):182-192. PubMed ID: 34672379 [TBL] [Abstract][Full Text] [Related]
20. Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer. McLeod AB; Stice JP; Wardell SE; Alley HM; Chang CY; McDonnell DP Prostate; 2018 Mar; 78(4):266-277. PubMed ID: 29243324 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]